CSS
CTMX icon

Cubist Systematic Strategies’s CytomX Therapeutics CTMX Stock Holding History

Cubist Systematic Strategies’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-98,383
Closed -$101K – 2968
2024
Q4 		$101K Buy
98,383
+73,923
+302% +$79.5K ﹤0.01% 2709
2024
Q3 		$28.9K Sell
24,460
-57,594
-70% -$73.2K ﹤0.01% 2797
2024
Q2 		$100K Buy
82,054
+40,309
+97% +$80.2K ﹤0.01% 2627
2024
Q1 		$91K Buy
+41,745
New +$77K ﹤0.01% 3288
2022
Q3 		– Sell
-9,346
Closed -$17K – 4463
2022
Q2 		$17K Hold
9,346
– – ﹤0.01% 4233
2022
Q1 		$25K Hold
9,346
– – ﹤0.01% 3462
2021
Q4 		$40K Hold
9,346
– – ﹤0.01% 3330
2021
Q3 		$48K Sell
9,346
-160
-2% -$856 ﹤0.01% 2839
2021
Q2 		$60K Hold
9,506
– – ﹤0.01% 2771
2021
Q1 		$73K Sell
9,506
-28,341
-75% -$224K ﹤0.01% 2693
2020
Q4 		$248K Buy
37,847
+13,803
+57% +$98.6K ﹤0.01% 2128
2020
Q3 		$160K Buy
24,044
+17,759
+283% +$132K ﹤0.01% 2191
2020
Q2 		$52K Sell
6,285
-7,371
-54% -$68.5K ﹤0.01% 2268
2020
Q1 		$105K Buy
13,656
+7
+0.1% +$49 ﹤0.01% 1899
2019
Q4 		$113K Buy
+13,649
New +$92.1K ﹤0.01% 2169
2019
Q3 		– Sell
-46,779
Closed -$525K – 2254
2019
Q2 		$525K Buy
46,779
+31,601
+208% +$331K 0.01% 1447
2019
Q1 		$163K Sell
15,178
-23,768
-61% -$351K 0.01% 1871
2018
Q4 		$588K Buy
38,946
+14,023
+56% +$208K 0.03% 859
2018
Q3 		$461K Buy
24,923
+16,598
+199% +$378K 0.03% 885
2018
Q2 		$190K Sell
8,325
-12,754
-61% -$326K 0.01% 1373
2018
Q1 		$600K Sell
21,079
-5,648
-21% -$161K 0.04% 700
2017
Q4 		$564K Buy
+26,727
New +$554K 0.03% 821
2017
Q3 		– Sell
-11,235
Closed -$174K – 1865
2017
Q2 		$174K Buy
+11,235
New +$169K 0.01% 1336

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cubist Systematic Strategies's CTMX Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 98,383 shares — an estimated $101K sold.

Cubist Systematic Strategies first reported a position in CTMX in Q2 2017 and held it in 23 quarters. The position peaked at $600K in Q1 2018. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 98,383 CytomX Therapeutics shares in Q1 2025, an estimated $101K.
  • Cubist Systematic Strategies first reported a position in CytomX Therapeutics in Q2 2017 and held it in 23 quarters.
  • Cubist Systematic Strategies's CytomX Therapeutics position peaked at $600K in Q1 2018.
  • 66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.